GlassScriptPhysician profile
Craig Kuntz
NPI 1790778918
$4,044.81
in general payments reported to CMS, 2019-2025
21 companies · $608 in 2025
The $608 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $488 · 2021: $207 · 2022: $1,355 · 2023: $482 · 2024: $498 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,625.49 | 2019-2024 | Rocklatan |
| Bausch & Lomb Americas INC. | $359.87 | 2022-2025 | Miebo, Infuse, Xiidra |
| Sun Pharmaceutical Industries INC. | $341.12 | 2019-2025 | Xelpros, Cequa, Bromsite |
| Coopervision INC. | $302.88 | 2022-2025 | Myday Contact Lens, Clariti Contact Lens |
| Tarsus Pharmaceuticals, INC. | $180.54 | 2024-2025 | Xdemvy |
| Allergan, INC. | $178.40 | 2019-2021 | |
| Dompe US, INC. | $171.27 | 2023-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $124.90 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.76 | 2019 | |
| Apellis Pharmaceuticals, INC. | $116.52 | 2025 | Syfovre |
| Horizon Therapeutics Plc | $114.25 | 2022-2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $74.11 | 2024-2025 | Acthar |
| Amgen INC. | $69.86 | 2024-2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $56.65 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $48.45 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $47.08 | 2023 | |
| Genmab U.S., INC. | $32.27 | 2024 | Tivdak |
| Thea Pharma INC. | $23.57 | 2025 | Iyuzeh |
| Biotissue Holdings INC. | $20.79 | 2023 | |
| Oyster Point Pharma, INC. | $17.49 | 2023 | Tyrvaya |
| Glaukos Corporation | $14.54 | 2024 | Idose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Kuntz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.